The Office of Fair Trading (OFT) has approved the proposed joint venture between GlaxoSmithKline (GSK) and Pfizer in relation to their HIV pharmaceuticals businesses. GSK currently manufactures and sells 8 HIV drugs, including Combivir, Kivexa/Epzicom, and Trizivir. Pfizer manufactures and sells only one drug, Selzentry. Both companies currently have a number of HIV drugs in the development phase. In its decision, published on 21 July 2009, the OFT considered that GSK and Pfizer were only competitive in relation to 'salvage' treatments within the market for HIV drugs and as a result the joint venture would only result in an incremental increase (up to 10%) of market share. The OFT considered it unlikely that the joint venture would result in a substantial lessening of competition within the market for HIV drugs. Consequently, the OFT decided not to refer the transaction to the Competition Commission for further review.